JP2019031565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019031565A5 JP2019031565A5 JP2018207426A JP2018207426A JP2019031565A5 JP 2019031565 A5 JP2019031565 A5 JP 2019031565A5 JP 2018207426 A JP2018207426 A JP 2018207426A JP 2018207426 A JP2018207426 A JP 2018207426A JP 2019031565 A5 JP2019031565 A5 JP 2019031565A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- drug conjugate
- acid sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38793310P | 2010-09-29 | 2010-09-29 | |
| US61/387,933 | 2010-09-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016243252A Division JP2017110002A (ja) | 2010-09-29 | 2016-12-15 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020110083A Division JP7042872B2 (ja) | 2010-09-29 | 2020-06-26 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019031565A JP2019031565A (ja) | 2019-02-28 |
| JP2019031565A5 true JP2019031565A5 (enExample) | 2019-05-09 |
| JP6726258B2 JP6726258B2 (ja) | 2020-07-22 |
Family
ID=45871300
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013531875A Active JP6083871B2 (ja) | 2010-09-29 | 2011-09-29 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2016243252A Withdrawn JP2017110002A (ja) | 2010-09-29 | 2016-12-15 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2018207426A Active JP6726258B2 (ja) | 2010-09-29 | 2018-11-02 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2018207295A Pending JP2019031563A (ja) | 2010-09-29 | 2018-11-02 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2018207044A Pending JP2019055958A (ja) | 2010-09-29 | 2018-11-02 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2020110083A Active JP7042872B2 (ja) | 2010-09-29 | 2020-06-26 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2022039841A Active JP7370405B2 (ja) | 2010-09-29 | 2022-03-15 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2023178591A Active JP7688088B6 (ja) | 2010-09-29 | 2023-10-17 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2025085582A Pending JP2025113404A (ja) | 2010-09-29 | 2025-05-22 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013531875A Active JP6083871B2 (ja) | 2010-09-29 | 2011-09-29 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2016243252A Withdrawn JP2017110002A (ja) | 2010-09-29 | 2016-12-15 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207295A Pending JP2019031563A (ja) | 2010-09-29 | 2018-11-02 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2018207044A Pending JP2019055958A (ja) | 2010-09-29 | 2018-11-02 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2020110083A Active JP7042872B2 (ja) | 2010-09-29 | 2020-06-26 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2022039841A Active JP7370405B2 (ja) | 2010-09-29 | 2022-03-15 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2023178591A Active JP7688088B6 (ja) | 2010-09-29 | 2023-10-17 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| JP2025085582A Pending JP2025113404A (ja) | 2010-09-29 | 2025-05-22 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US8637642B2 (enExample) |
| EP (3) | EP3903812A1 (enExample) |
| JP (9) | JP6083871B2 (enExample) |
| KR (10) | KR101851746B1 (enExample) |
| CN (2) | CN105567717B (enExample) |
| AU (1) | AU2011312417B2 (enExample) |
| BR (1) | BR112013007309B1 (enExample) |
| CA (1) | CA2811644C (enExample) |
| CY (3) | CY1121023T1 (enExample) |
| DK (2) | DK3409287T5 (enExample) |
| EA (2) | EA027887B1 (enExample) |
| ES (2) | ES2874306T3 (enExample) |
| FR (1) | FR22C1050I2 (enExample) |
| HR (1) | HRP20181154T8 (enExample) |
| HU (3) | HUE054855T2 (enExample) |
| IL (6) | IL311145B2 (enExample) |
| LT (2) | LT2621526T (enExample) |
| LU (1) | LUC00280I2 (enExample) |
| MX (4) | MX369679B (enExample) |
| NL (1) | NL301198I2 (enExample) |
| NO (1) | NO2022039I1 (enExample) |
| PH (2) | PH12013500542A1 (enExample) |
| PL (2) | PL2621526T3 (enExample) |
| PT (2) | PT3409287T (enExample) |
| RS (1) | RS57483B1 (enExample) |
| SI (2) | SI3409287T1 (enExample) |
| SM (1) | SMT201800365T1 (enExample) |
| TW (7) | TWI814373B (enExample) |
| UA (1) | UA110495C2 (enExample) |
| WO (1) | WO2012047724A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105567717B (zh) * | 2010-09-29 | 2019-10-29 | 艾更斯司股份有限公司 | 结合于191p4d12蛋白的抗体药物偶联物(adc) |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| SG11201405130UA (en) | 2012-02-24 | 2014-11-27 | Stemcentrx Inc | Anti sez6 antibodies and methods of use |
| SMT201700467T1 (it) | 2012-02-24 | 2017-11-15 | Abbvie Stemcentrx Llc | Modulatori di dll3 e metodi di uso |
| PL2887959T3 (pl) * | 2012-08-23 | 2019-04-30 | Agensys Inc | Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7 |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| JP2016509014A (ja) | 2013-02-08 | 2016-03-24 | ステムセントリックス， インコーポレイテッド | 新規の多特異的構成物 |
| TR201908761T4 (tr) | 2013-02-22 | 2019-07-22 | Abbvie Stemcentrx Llc | Antidll3-antikor-pbd konjugatları ve kullanımları. |
| KR20160046914A (ko) | 2013-08-28 | 2016-04-29 | 스템센트알엑스 인코포레이티드 | 신규한 ｓｅｚ6 조절물질 및 사용방법 |
| CA2922544A1 (en) * | 2013-08-28 | 2015-03-05 | Stemcentrx, Inc. | Engineered anti-dll3 conjugates and methods of use |
| MX377339B (es) | 2013-08-28 | 2025-03-06 | Abbvie Stemcentrx Llc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones. |
| EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| JP2017511376A (ja) * | 2014-03-21 | 2017-04-20 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| CN104212698A (zh) * | 2014-10-01 | 2014-12-17 | 南京飞马食品有限公司 | 一种发芽糙米醋的制作方法 |
| KR102790429B1 (ko) | 2015-03-09 | 2025-04-04 | 어젠시스 인코포레이티드 | Flt3 단백질에 결합하는 항체 약물 콘쥬게이트(adc) |
| US11173213B2 (en) * | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| EP3347048B1 (en) * | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| JP2020501506A (ja) | 2016-09-07 | 2020-01-23 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | 抗ＮＫｐ４６抗体およびその治療的使用 |
| CN110234348B (zh) | 2016-12-16 | 2024-06-25 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
| CN110392697A (zh) * | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| TWI870338B (zh) * | 2017-06-05 | 2025-01-21 | 美商艾澤西公司 | 粘附分子-4結合蛋白及其使用方法 |
| AU2018329937B2 (en) * | 2017-09-07 | 2024-09-12 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and nectin4 |
| CN111163809B (zh) | 2017-09-19 | 2024-07-02 | 保罗·谢勒学院 | 转谷氨酰胺酶缀合方法和接头 |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| BR112020018948A2 (pt) | 2018-03-23 | 2021-01-05 | Seattle Genetics, Inc. | Uso de conjugados de fármaco e anticorpo que compreendem agentes de interrupção de tubulina para tratar tumor sólido |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| MX2021006430A (es) | 2018-12-03 | 2021-09-14 | Agensys Inc | Composiciones farmacéuticas que comprenden conjugados de fármaco-anticuerpo anti-191p4d12 y métodos de uso de las mismas. |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| CA3150274A1 (en) * | 2019-08-13 | 2021-02-18 | Agensys, Inc. | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| TW202133885A (zh) * | 2019-11-25 | 2021-09-16 | 美商艾澤西公司 | 利用與191p4d12蛋白結合之抗體藥物結合物(adc)治療癌症 |
| ES3014740T3 (en) | 2020-01-31 | 2025-04-24 | Innate Pharma | Treatment of cancer |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| AU2021243073A1 (en) * | 2020-03-25 | 2022-10-13 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody drug conjugate and use thereof |
| US20230173093A1 (en) | 2020-04-10 | 2023-06-08 | Seagen Inc. | Charge variant linkers |
| AU2021293183A1 (en) * | 2020-06-18 | 2023-02-16 | Bioatla, Inc. | Conditionally active anti-Nectin-4 antibodies |
| CN116209464A (zh) * | 2020-06-19 | 2023-06-02 | 艾更斯司股份有限公司 | 用于用抗体药物偶联物(adc)治疗癌症的方法中的标志物 |
| EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| CN116234564A (zh) | 2020-09-16 | 2023-06-06 | 四川科伦博泰生物医药股份有限公司 | 抗Nectin-4抗体、包含所述抗体的缀合物及其应用 |
| KR20230091885A (ko) * | 2020-09-17 | 2023-06-23 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법 |
| US20230364254A1 (en) * | 2020-10-11 | 2023-11-16 | Agensys, Inc. | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| WO2022084560A1 (en) | 2020-10-25 | 2022-04-28 | Araris Biotech Ag | Means and methods for producing antibody-linker conjugates |
| IL302402A (en) | 2020-11-08 | 2023-06-01 | Seagen Inc | Combination therapy |
| KR102408221B1 (ko) * | 2020-11-10 | 2022-06-13 | 삼성메카닉스 (주) | 그리드 커플링 성형장치 |
| CA3196198A1 (en) | 2020-11-25 | 2022-06-02 | Manel KRAIEM | Treatment of cancer |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2022198231A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CA3212651A1 (en) | 2021-03-31 | 2022-10-06 | Emergence Therapeutics Ag | Anti-nectin-4-antibodies and uses thereof |
| EP4086284A1 (en) | 2021-05-07 | 2022-11-09 | Emergence Therapeutics AG | Anti-nectin-4 antibody exatecan conjugates |
| AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Genmab A/S | Folr1 binding agents, conjugates thereof and methods of using the same |
| TW202308699A (zh) | 2021-04-23 | 2023-03-01 | 美商普方生物製藥美國公司 | Ｃｄ７０結合劑、其結合物及其使用方法 |
| US20240269307A1 (en) | 2021-04-26 | 2024-08-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereof |
| CN117580593A (zh) | 2021-05-28 | 2024-02-20 | 思进公司 | 蒽环霉素抗体结合物 |
| KR20240042109A (ko) * | 2021-08-13 | 2024-04-01 | 어젠시스 인코포레이티드 | 191P4D12 단백질에 결합하는 항체 약물 접합체[Antibody Drug Conjugate, ADC]로 비근침윤성 방광암[Non-muscle invasive bladder cancer, NMIBC]을 치료하는 방법 |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| CA3238167A1 (en) | 2021-11-19 | 2023-05-25 | Maria Leia Smith | Gpc3 binding agents, conjugates thereof and methods of using the same |
| KR20250004952A (ko) | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
| US20250205353A1 (en) | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| JP7690922B2 (ja) * | 2022-05-02 | 2025-06-11 | 株式会社三洋物産 | 遊技機 |
| JP7740118B2 (ja) * | 2022-05-02 | 2025-09-17 | 株式会社三洋物産 | 遊技機 |
| WO2023221971A1 (zh) | 2022-05-16 | 2023-11-23 | 江苏恒瑞医药股份有限公司 | 一种含抗Nectin-4抗体药物偶联物的药物组合物及其用途 |
| KR20250017209A (ko) | 2022-05-25 | 2025-02-04 | 이나뜨 파르마 에스.에이. | 넥틴-4 결합제 |
| US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| EP4285935A1 (en) | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| EP4309676A1 (en) | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| EP4324849A1 (en) | 2022-08-18 | 2024-02-21 | Emergence Therapeutics AG | Humanized anti-nectin-4 antibodies |
| WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
| EP4344707A1 (en) | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
| AU2023350248A1 (en) | 2022-09-30 | 2025-04-17 | Shanghai De Novo Pharmatech Co., Ltd. | Benzazepine derivative, conjugate containing same, and use thereof |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| EP4461317A1 (en) | 2023-05-12 | 2024-11-13 | Emergence Therapeutics GmbH | Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof |
| TW202504637A (zh) | 2023-06-13 | 2025-02-01 | 美商艾德森特克斯治療股份有限公司 | 與結合至nectin-4蛋白之抗體及抗體藥物結合物(adc)相關之方法及組合物 |
| EP4534102A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025162492A1 (zh) * | 2024-01-29 | 2025-08-07 | 甘李药业股份有限公司 | 一种连接子、配体-药物偶联物及其医药用途 |
| WO2025224297A1 (en) | 2024-04-26 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to tgfbi and uses thereof |
Family Cites Families (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| FI102355B1 (fi) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| DE69626849T2 (de) | 1995-12-22 | 2003-12-24 | Bristol-Myers Squibb Co., Princeton | Verzweigte hydrazongruppen enthaltende kuppler |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| ATE371721T1 (de) | 1996-10-15 | 2007-09-15 | Univ California | Tiermodelle für die menschliche prostatakrebsfortschreitung |
| AU5923398A (en) | 1997-01-21 | 1998-08-07 | Human Genome Sciences, Inc. | Polynucleotides and polypeptides encoding receptors |
| CA2282504A1 (en) | 1997-02-25 | 1998-08-27 | Jun-Ping Xu | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| US20030065156A1 (en) | 1997-12-23 | 2003-04-03 | Williams Lewis T. | Novel human genes and gene expression products I |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2272061T5 (es) | 1998-04-15 | 2012-02-24 | Merck Serono Biodevelopment | Secuencia genómica de la proteína activadora de 5-lipoxigenasa (flap), marcadores polimórficos de la misma y métodos para la detección de asma. |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6264949B1 (en) | 1998-09-29 | 2001-07-24 | Mount Sinai School Of Medicine Of New York University | Noninvasive agents for diagnosis and prognosis of the progression of fibrosis |
| US20020137160A1 (en) | 1998-12-17 | 2002-09-26 | Byatt John C | Nucleic acid and other molecules associated with lactation and muscle and fat deposition |
| US7160694B2 (en) | 1999-06-14 | 2007-01-09 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding TANGO405 and functional fragments and uses thereof |
| JP2003518920A (ja) | 1999-07-02 | 2003-06-17 | カイロン コーポレイション | 新規なヒト遺伝子および遺伝子発現産物 |
| EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| JP2003533968A (ja) | 1999-09-03 | 2003-11-18 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体 |
| WO2001018016A1 (en) | 1999-09-10 | 2001-03-15 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| WO2001022920A2 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| WO2001051628A2 (en) | 2000-01-14 | 2001-07-19 | Millennium Pharmaceuticals, Inc. | Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| CA2393002A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20020090672A1 (en) | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| AU2001243142A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001241541A1 (en) | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| CN1169954C (zh) | 2000-03-09 | 2004-10-06 | 上海市肿瘤研究所 | 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸 |
| WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2001090304A2 (en) | 2000-05-19 | 2001-11-29 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001094629A2 (en) | 2000-06-05 | 2001-12-13 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| WO2002010449A2 (en) | 2000-07-28 | 2002-02-07 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
| US7175849B2 (en) | 2000-10-05 | 2007-02-13 | Immunex Corporation | Nectin polypeptides |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| KR100770188B1 (ko) * | 2000-12-20 | 2007-10-25 | 데이진 가부시키가이샤 | 폴리에스테르 혼섬사의 제조 방법 |
| MXPA03006617A (es) | 2001-01-24 | 2004-12-02 | Protein Design Labs Inc | Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho. |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| AU2002251841A1 (en) | 2001-01-30 | 2002-08-12 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| AU2002338431A1 (en) | 2001-04-04 | 2002-11-05 | Quark Biotech, Inc. | Sequence characteristics of bladder cancer |
| CA2444691A1 (en) | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| CA2449482A1 (en) | 2001-06-05 | 2002-12-12 | Exelixis, Inc. | Chds as modifiers of the p53 pathway and methods of use |
| US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| MXPA03011979A (es) | 2001-06-18 | 2005-04-08 | Eos Biotechnology Inc | Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario. |
| US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| CA2453965C (en) | 2001-07-19 | 2016-01-19 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| MXPA04002593A (es) | 2001-09-18 | 2004-05-31 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumor. |
| JP4200100B2 (ja) | 2001-11-07 | 2008-12-24 | アジェンシス，インコーポレイテッド | 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質 |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| AU2003276494A1 (en) | 2002-06-13 | 2004-01-23 | Regulome Corporation | Functional sites |
| JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| AU2008202217B2 (en) * | 2002-08-16 | 2012-07-26 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 191PAD12(b) useful in treatment and detection of cancer |
| WO2004016733A2 (en) * | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US8017170B2 (en) | 2002-08-29 | 2011-09-13 | University Of Massachusetts | Utilization of emulsion interface engineering to produce oxidatively stable lipid delivery systems |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CN104998273A (zh) | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| CA2560919A1 (en) | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
| WO2005111076A1 (en) | 2004-05-12 | 2005-11-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4 (n4) as a marker for cancer prognosis |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| EP3088004B1 (en) | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| CN101500590A (zh) * | 2005-03-31 | 2009-08-05 | 阿根西斯公司 | 与161p2f10b蛋白结合的抗体和相关分子 |
| AU2006230563B8 (en) | 2005-03-31 | 2010-06-17 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
| WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| MX2009003938A (es) | 2006-10-27 | 2009-04-24 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
| JP5394246B2 (ja) | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| CN105567717B (zh) | 2010-09-29 | 2019-10-29 | 艾更斯司股份有限公司 | 结合于191p4d12蛋白的抗体药物偶联物(adc) |
-
2011
- 2011-09-29 CN CN201510519846.0A patent/CN105567717B/zh active Active
- 2011-09-29 UA UAA201305358A patent/UA110495C2/uk unknown
- 2011-09-29 IL IL311145A patent/IL311145B2/en unknown
- 2011-09-29 MX MX2017006479A patent/MX369679B/es unknown
- 2011-09-29 EA EA201300411A patent/EA027887B1/ru unknown
- 2011-09-29 PT PT181718032T patent/PT3409287T/pt unknown
- 2011-09-29 TW TW111117461A patent/TWI814373B/zh active
- 2011-09-29 IL IL290591A patent/IL290591B2/en unknown
- 2011-09-29 PH PH1/2013/500542A patent/PH12013500542A1/en unknown
- 2011-09-29 TW TW104140581A patent/TWI651096B/zh active
- 2011-09-29 BR BR112013007309-8A patent/BR112013007309B1/pt active IP Right Grant
- 2011-09-29 HR HRP20181154TT patent/HRP20181154T8/hr unknown
- 2011-09-29 TW TW107103146A patent/TWI674112B/zh active
- 2011-09-29 LT LTEP11831345.1T patent/LT2621526T/lt unknown
- 2011-09-29 KR KR1020177031187A patent/KR101851746B1/ko active Active
- 2011-09-29 KR KR1020227001399A patent/KR102504750B1/ko active Active
- 2011-09-29 PT PT118313451T patent/PT2621526T/pt unknown
- 2011-09-29 SM SM20180365T patent/SMT201800365T1/it unknown
- 2011-09-29 DK DK18171803.2T patent/DK3409287T5/da active
- 2011-09-29 HU HUE18171803A patent/HUE054855T2/hu unknown
- 2011-09-29 RS RS20180854A patent/RS57483B1/sr unknown
- 2011-09-29 PL PL11831345T patent/PL2621526T3/pl unknown
- 2011-09-29 TW TW100135340A patent/TWI524901B/zh active
- 2011-09-29 DK DK11831345.1T patent/DK2621526T3/en active
- 2011-09-29 KR KR1020237006492A patent/KR102595129B1/ko active Active
- 2011-09-29 SI SI201131986T patent/SI3409287T1/sl unknown
- 2011-09-29 KR KR1020237028203A patent/KR102627947B1/ko active Active
- 2011-09-29 ES ES18171803T patent/ES2874306T3/es active Active
- 2011-09-29 TW TW109135992A patent/TWI764324B/zh active
- 2011-09-29 TW TW112112533A patent/TWI882308B/zh active
- 2011-09-29 AU AU2011312417A patent/AU2011312417B2/en active Active
- 2011-09-29 WO PCT/US2011/054054 patent/WO2012047724A1/en not_active Ceased
- 2011-09-29 TW TW107143990A patent/TWI720377B/zh active
- 2011-09-29 US US13/249,111 patent/US8637642B2/en not_active Ceased
- 2011-09-29 SI SI201131535T patent/SI2621526T1/sl unknown
- 2011-09-29 KR KR1020217026806A patent/KR102353283B1/ko active Active
- 2011-09-29 JP JP2013531875A patent/JP6083871B2/ja active Active
- 2011-09-29 MX MX2016003743A patent/MX347954B/es unknown
- 2011-09-29 EP EP21166650.8A patent/EP3903812A1/en active Pending
- 2011-09-29 KR KR1020247001866A patent/KR102801509B1/ko active Active
- 2011-09-29 PL PL18171803T patent/PL3409287T3/pl unknown
- 2011-09-29 ES ES11831345.1T patent/ES2680624T3/es active Active
- 2011-09-29 KR KR1020197004139A patent/KR102166408B1/ko active Active
- 2011-09-29 MX MX2013003419A patent/MX337873B/es active IP Right Grant
- 2011-09-29 IL IL319612A patent/IL319612A/en unknown
- 2011-09-29 HU HUE11831345A patent/HUE038908T2/hu unknown
- 2011-09-29 KR KR1020137011094A patent/KR20130130709A/ko not_active Abandoned
- 2011-09-29 CA CA2811644A patent/CA2811644C/en active Active
- 2011-09-29 CN CN201180056969.5A patent/CN103402538B/zh active Active
- 2011-09-29 EP EP18171803.2A patent/EP3409287B9/en active Active
- 2011-09-29 KR KR1020207028941A patent/KR102295534B1/ko active Active
- 2011-09-29 EP EP11831345.1A patent/EP2621526B1/en active Active
- 2011-09-29 KR KR1020257013489A patent/KR20250058780A/ko active Pending
- 2011-09-29 PH PH1/2017/501461A patent/PH12017501461B1/en unknown
- 2011-09-29 EA EA201790850A patent/EA201790850A1/ru unknown
-
2013
- 2013-03-14 US US13/830,899 patent/US9078931B2/en active Active
- 2013-03-22 MX MX2019013655A patent/MX2019013655A/es unknown
- 2013-03-24 IL IL225460A patent/IL225460B/en active IP Right Grant
-
2015
- 2015-07-13 US US14/798,302 patent/US9314538B2/en active Active
-
2016
- 2016-03-14 US US15/069,853 patent/US9962454B2/en active Active
- 2016-12-15 JP JP2016243252A patent/JP2017110002A/ja not_active Withdrawn
-
2017
- 2017-09-06 US US15/697,146 patent/USRE48389E1/en active Active
-
2018
- 2018-04-02 US US15/943,527 patent/US10894090B2/en active Active
- 2018-07-31 CY CY181100790T patent/CY1121023T1/el unknown
- 2018-10-02 IL IL262073A patent/IL262073B/en active IP Right Grant
- 2018-11-02 JP JP2018207426A patent/JP6726258B2/ja active Active
- 2018-11-02 JP JP2018207295A patent/JP2019031563A/ja active Pending
- 2018-11-02 JP JP2018207044A patent/JP2019055958A/ja active Pending
-
2020
- 2020-06-26 JP JP2020110083A patent/JP7042872B2/ja active Active
- 2020-11-13 IL IL278696A patent/IL278696B/en unknown
- 2020-12-15 US US17/122,786 patent/US11559582B2/en active Active
-
2021
- 2021-05-18 CY CY20211100429T patent/CY1124166T1/el unknown
-
2022
- 2022-03-15 JP JP2022039841A patent/JP7370405B2/ja active Active
- 2022-09-28 NL NL301198C patent/NL301198I2/nl unknown
- 2022-09-29 NO NO2022039C patent/NO2022039I1/no unknown
- 2022-10-04 HU HUS2200043C patent/HUS2200043I1/hu unknown
- 2022-10-05 FR FR22C1050C patent/FR22C1050I2/fr active Active
- 2022-10-05 CY CY2022029C patent/CY2022029I2/el unknown
- 2022-10-05 LT LTPA2022012C patent/LTC2621526I2/lt unknown
- 2022-10-06 LU LU00280C patent/LUC00280I2/fr unknown
- 2022-12-14 US US18/066,156 patent/US20230346968A1/en not_active Abandoned
-
2023
- 2023-10-17 JP JP2023178591A patent/JP7688088B6/ja active Active
-
2025
- 2025-05-22 JP JP2025085582A patent/JP2025113404A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019031565A5 (enExample) | ||
| JP2023179713A5 (enExample) | ||
| JP2017110002A5 (enExample) | ||
| JP2025113404A5 (enExample) | ||
| JP2020152735A5 (enExample) | ||
| JP2022031635A5 (enExample) | ||
| JP2024016177A5 (enExample) | ||
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| IL311145B2 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| IL268745A (en) | Antibody drug conjugates (adc) that bind to 158p1d7 proteins | |
| JP2013543498A5 (enExample) | ||
| JP2016538318A5 (enExample) | ||
| JP2009511480A5 (enExample) | ||
| JP2015533781A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2020518600A5 (enExample) | ||
| JPWO2020122034A5 (enExample) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2015534579A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| JP2010523469A5 (enExample) | ||
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2015527318A5 (enExample) | ||
| JP2014520088A5 (enExample) | ||
| JP2017522861A5 (enExample) |